Publicação de Dilmara Reischak

#AntibioticResistance, zoonotic spillovers, climate-driven outbreaks—what’s the biggest infectious threat for 2025? Experts are narrowing it down: Via The Conversation UK 

What's wrong with saying tuberculosis (TB) patients?🤔 A while ago we stopped saying #TBPatients and started saying people with TB (PwTB)... Why is that? When we reduce the humanity of a person or community to the disease that affects them and label them only as patients, we stop seeing all the dimensions that cut across their lives and reduce them to be only numbers in health statistics and study subjects.📈📊 👉️At KNCV Tuberculosis Foundation we are focusing our efforts to #PeopleCentered strategies and tackling stigma associated with #TB and other infectious diseases through our approaches: reducing the tendency to label, blame, shame, and control by actively cultivating awareness of our own judgments, and so promoting meaningful shift in attitudes and use of language! Ending #TBStigma is part of our goal to ending TB!!🤝 🔗If you want to know more about TB stigma and our approaches visit: https://lnkd.in/g-RfKUWG #EndTB #TogetherWeCanEndTB #tuberculosis #stigma #InclusiveCommunication

Our BIOFIRE® FILMARRAY® Tropical Fever Panel has received U.S. FDA Special 510(k) clearance ! This cutting-edge PCR testing solution is designed to swiftly and accurately identify pathogens responsible for tropical fevers, including malaria, chikungunya, dengue, and leptospirosis. With this 7th BioFire panel, we aim to further accelerate the globalization of our BioFire franchise, delivering faster and more precise diagnostics, ultimately improving patient outcomes. This marks a significant step forward in our commitment to addressing the diagnostic needs for infectious diseases that are prevalent across the globe. This milestone demonstrates once again our innovative approach to syndromic testing and our unwavering commitment to enhancing public health #ProudOfOurTeams

🌍 As temperatures rise and rainfall trends shift, the transmission patterns of mosquito-borne diseases like #malaria are evolving, presenting new challenges. This #WorldMosquitoDay, it’s critical to acknowledge how #ClimateChange is altering the malaria landscape. To stay ahead, we need adaptive solutions—from medicines 💊 and #vaccines 💉 to innovative vector control methods 🛡. The fight against malaria is evolving, and our approach must evolve with it. Now more than ever, investing in new innovative solutions and expanding access to current tools is crucial to protect communities and drive #GlobalHealth progress.

📢 We are announcing today that our BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever, has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance. Presentation of tropical fever infections – including malaria, chikungunya or dengue – are often non-specific and overlapping, complicating efforts to distinguish mild self-limiting illness from more severe diseases that require prompt and targeted treatment. The BIOFIRE® FILMARRAY® Tropical Fever (TF) Panel allows healthcare providers to quickly identify pathogens commonly found in patients presenting with suspected tropical fever infections in one fast easy-to-use test. 📰 Read the full press release: https://lnkd.in/eD_-tXue #PioneeringDiagnostics

The Centers for Disease Control and Prevention (CDC) has issued a recent Health Advisory regarding a significant increase in dengue virus infections across the United States in 2024. This year marks the highest global incidence of dengue on record, with troubling numbers exceeding 9.7 million. Experts attribute this surge, in part, to the effects of climate change, which create ideal breeding grounds for mosquitoes that transmit dengue. The alarming rise in dengue cases underscores the critical need for effective yet environmentally responsible strategies to combat mosquito-borne illnesses, especially as climate change alters ecosystems and expands mosquito habitats. https://lnkd.in/eHFe_HVb #PublicHealth #Sustainability #Mosqitter #ClimateChange #mosquitotrap

Pneumonia remains a major infectious disease with high morbidity, mortality, and healthcare costs worldwide. However, in approximately 50% of community-acquired pneumonia (CAP) cases, the causative pathogens cannot be identified due to limitations in traditional microbiological methods, making timely and accurate diagnosis a challenge. We will share our experience with a new automated solution that addresses the limitations of current tests. With the peak season approaching, laboratories are being challenged by the increasing number of tests. Discover how Urinary Antigen Tests (UATs) for 𝑆𝑡𝑟𝑒𝑝𝑡𝑜𝑐𝑜𝑐𝑐𝑢𝑠 𝑝𝑛𝑒𝑢𝑚𝑜𝑛𝑖𝑎𝑒 and 𝐿𝑒𝑔𝑖𝑜𝑛𝑒𝑙𝑙𝑎 𝑝𝑛𝑒𝑢𝑚𝑜𝑝ℎ𝑖𝑙𝑎 can improve workflow, speed diagnosis and enhance patient management. 📅 November 7, 2024 Save the date and register for the webinar 🔗 https://lnkd.in/dC9w_JSq

🔬 𝗥𝗮𝗽𝗶𝗱 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗖𝗮𝗻𝗱𝗶𝗱𝗮 𝗮𝘂𝗿𝗶𝘀 𝗙𝘂𝗻𝗴𝗮𝗹 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 🍄   𝘾𝙖𝙣𝙙𝙞𝙙𝙖 𝙖𝙪𝙧𝙞𝙨 is on the rise, causing severe infections and posing significant risks in healthcare environments. With 𝗰𝗮𝘀𝗲𝘀 𝗱𝗼𝘂𝗯𝗹𝗶𝗻𝗴 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆 in recent years and invasive infections carrying a over 𝟯𝟱% 𝗺𝗼𝗿𝘁𝗮𝗹𝗶𝘁𝘆 𝗿𝗮𝘁𝗲, the need for swift and accurate detection has never been more urgent!   𝗧𝗵𝗲 𝗩𝗶𝘃𝗮𝗹𝘆𝘁𝗶𝗰 𝗖𝗮𝗻𝗱𝗶𝗱𝗮 𝗮𝘂𝗿𝗶𝘀 𝗧𝗲𝘀𝘁 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘀: ⌛ Results in under 1 hour from just a 300μl clinical swab sample. 4️⃣ A simple, 4-step automated process. 🎯 Accurate detection with real-time PCR technology.   These features empower healthcare providers to take 𝗾𝘂𝗶𝗰𝗸, 𝗶𝗻𝗳𝗼𝗿𝗺𝗲𝗱 𝗮𝗰𝘁𝗶𝗼𝗻, 𝗶𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 and 𝗰𝘂𝗿𝗯𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝗽𝗿𝗲𝗮𝗱 of this dangerous fungus.   Learn how Randox and Vivalytic are revolutionising fungal infection diagnostics. 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴: https://lnkd.in/ecJC3jVn   For further details, contact marketing@randox.com or visit https://lnkd.in/eAegTUYa   #CandidaAuris #FungalInfections #RapidDiagnostics #PublicHealth #Vivalytic #Randox

Timely diagnosis of fungal infections is crucial, as symptoms often overlap with bacterial or viral infections. Traditional diagnostic methods can be slow and inaccurate, leading to the overuse of antifungal drugs and rising resistance. IMMY plays an instrumental role in improving health outcomes for patients suffering from fungal diseases. New advances in lab-based and point-of-care tests are changing the game, enabling rapid, culture-free identification of infections. This allows for targeted treatments and better antifungal stewardship, improving patient outcomes and preserving treatment options for the future. Together, we can prioritize early diagnosis and fight antifungal resistance. #FungalWeek24 #EarlyDiagnosis #AntifungalStewardship #IMMY #GlobalHealth #ThinkFugus #TestFungus